Dassault Aviation said it picked India's Reliance Defence as a partner for a big military combat deal on its own, countering a French online media report that said the Indian government insisted on the firm as a condition of the contract.
Prime minister Narendra Modi's purchase of 36 Rafale planes in a deal estimated to be worth $8.7 billion has become a political controversy and on Thursday (11) his rivals seized on the revelations by Mediapart as further evidence of wrongdoing.
The deal has faced scrutiny both on the price and the decision to choose billionaire Anil Ambani's Reliance as a local partner with no aeronautical expertise instead of the state-run Hindustan Aeronautics which has a long history of making planes.
The French news outlet said it had obtained a Dassault company document in which a senior executive is quoted as saying the group agreed to work with Reliance as an “imperative and obligatory” condition for securing the fighter contract.
Under India's defense procurement rules, any company selling equipment must invest at least 30 per cent of the contract in India as part of an "offset" clause to help build a domestic manufacturing base and reduce the country's dependence on imports.
Mediapart's report appeared to corroborate former French president Francois Hollande's comments last month that New Delhi had put pressure on Dassault to choose Reliance as the offset partner in a deal worth millions of dollars to the Indian company.
The deal was sealed when Hollande was in office.
But Dassault in a statement late on Wednesday (10) denied Delhi had a role in the choice of the partner.
It said it had committed to investing 50 per cent of the contract value to benefit the local economy and for that purpose had entered into a joint venture with the private Indian firm.
The joint venture, Dassault Reliance Aerospace Ltd (DRAL), was created in February last year and the foundation stone for the plant was laid in October in the western state of Maharashtra.
"Dassault Aviation has freely chosen to make a partnership with India's Reliance Group," it said. The plan is to produce parts for Dassault's Falcon 2000 business jets and, in a second step, components for the Rafale combat aircraft that the Indian military is buying to upgrade.
The company said it had trained an initial team of managers and workers and the first Falcon components will be delivered by the end of the year.
India picked the Rafale plane to replace its ageing fleet of Russian aircraft from a field that included Lockheed Martin F-16, Saab's Gripen, the Eurofighter Typhoon, Boeing 's F/A-18E/F Super Hornet and the Russian MiG-35.
The leader of the main opposition Congress party, Rahul Gandhi, said Modi had been silent on the allegations of wrongdoing in the deal.
"PM should come clean on the Rafale deal. He came to office with the express purpose of eliminating corruption and now we have a clear case of wrongdoing before us," Gandhi told reporters while the party distributed copies of the French report.
The defense ministry said it stood by its position that the government had no role to play in Dassault's selection of its local partner. Modi could not be reached for comment but members of his party have repeatedly derided the opposition saying they were undermining national security.
Reliance did not respond to a request for comment.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.